Clinical Trial Results of Motesanib's Effectiveness Against MTC

by: cancercompass

The drug motesanib has been found to help stabilize patients with medullary thyroid cancer (MTC). The supporting research was published recently in the Journal of Clinical Oncology.

Researchers analyzed 91 patients with advanced or metastatic, progressive or symptomatic MTC after receiving motesanib orally for up to 48 weeks. Treatments were stopped for patients experiencing unacceptable toxicity levels or disease progression.

The study abstract reports that 81% of patients who received motesanib achieved a stable disease state. In addition, 76% of patients saw a decrease in tumor size from baseline measurements.

Commonly experienced side effects were diarrhea, fatigue, hypothyroidism, hypertension and anorexia.

Are you currently taking part in clinical trials like this one? Help other cancer patients learn from your experiences at our Clinical Trials and Research Cancer Forum.